Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: A cardiff diabetes model analysis

Clinical Drug Investigation

Volumn 32, Issue 3, 2012, Pages 189-202

  Erhardt, Wilma ^a   Bergenheim, Klas ^b   Duprat Lomon, Isabelle ^a   McEwan, Phil ^c  

^a BRISTOL MYERS SQUIBB   (United States)

^b Bristol Myers Squibb ^*

^c Eastgate House   (United Kingdom)

Author keywords

Cost effectiveness; Glipizide; Metformin; Sulfonylureas; Type 2 diabetes mellitus

Indexed keywords

GLIPIZIDE; METFORMIN; SAXAGLIPTIN;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DISEASE COURSE; DRUG COST; FEMALE; GERMANY; HUMAN; HYPOGLYCEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SIMULATION; STATISTICAL MODEL; TREATMENT FAILURE; WEIGHT CHANGE;

ADAMANTANE; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84856909706     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11597060-000000000-00000     Document Type: Article

References (57)

1. Marre L, Vasmant G, Hadjadj R, et al. Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa. Diabetes Care 2000; 23 Suppl. 2: B40-8
2. Seufert J. Cardiovascular outcome studies in type 2 diabetes therapy. Deutsches Ärzteblatt 2006; 103 (4): A934-42
3. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25 (5): 815-21 (Pubitemid 41094276)
4. Weber C, Neeser K, Wenzel H, et al. Cost of type 2 diabetes in Germany over 8 years (the ROSSO study No. 2). J Med Econ 2006; 9 (1-4): 45-53 (Pubitemid 43844408)
5. Stock SA, Redaelli M, Wendland G, et al. Diabetes: prevalence and cost of illness in Germany. A study evaluating data from the statutory health insurance in Germany. Diabet Med 2005; 23 (3): 299-305
6. German Consumer Price Indices, Federal Statistics Office of Germany [online]. Available from URL: . de/jetspeed/portal/cms/Sites/destatis/Internet/ EN/Navigation/ Statistics/Preise/Verbraucherpreise/Tabellen.psml [Accessed 2011 Jan 20]
7. Matthaei S, Bierwirth R, Fritsche A, et al. Medical antihyperglycaemic treatment of type 2 diabetes mellitus: update of the evidence-based guideline of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2009; 117 (9): 522-57
8. Stratton IM, Adler AI, Neil HA, et al., On behalf of the UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-12 (Pubitemid 30609442)
9. Rubino A, McQuay LJ, Gough SC, et al. Delayed initiation of subcutaneous insulin therapy after failure of oral glucose-lowering agents in patients with type 2 diabetes: a population-based analysis in the UK. Diabetic Medicine 2007; 24: 1412-8 (Pubitemid 350179434)
10. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care 2005; 28: 2673-9
11. Dhillon S, Weber J. Saxagliptin. Drugs 2009; 69 (15): 2103-14
12. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17 (2): 161-71 (Pubitemid 36183142)
13. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009; 26 (3): 249-62
14. LaSalle JR. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. Postgrad Med 2010; 122 (1): 144-52
15. McEwan P, Peters JR, Bergenheim K, et al. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation costutility model (DiabForecaster). Curr Med Res Opin 2006; 22: 121-9 (Pubitemid 43106915)
16. McEwan P, Evans M, Kan H, et al. Understanding the interrelationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model. Diabetes Obes Metab 2010; 12: 431-6
17. McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes. Diabetes Obes Metab 2010; 12: 623-30
18. McEwan P, Bergenheim K, Yuan Y, et al. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care. Pharmacoeconomics 2010; 28: 665-74
19. Göke B, Gallwitz B, Eriksson J, et al., for the D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010 Nov; 64 (12): 1619-31
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352 (9131): 837-53
21. Saenz A, Fernandez-Esteban I, Mataix A, et al. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005 Oct 20; (3): CD002966
22. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 81 (2): 184-9
23. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355 (23): 2427-43 (Pubitemid 44903747)
24. Eastman RC, Javitt JC, Herman WH, et al. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997; 20 (5): 735-44 (Pubitemid 27202521)
25. The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the fourth Mount Hood challenge meeting. Diabetes Care 2007; 30: 1638-46
26. Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) outcomes model (UKPDS no. 68). Diabetologia 2004; 47: 1747-59 (Pubitemid 40022410)
27. Bayerisches Rotes Kreuz, Rettungsdienst im Landkreis Weilheim-Schongau: Der Rettungsdienst in Bayern [online]. Available from URL: . de/rettungsdienst/allgemeines [Accessed 2011 Jan 20]
28. Institut für das Entgeltsystem im Krankenhaus InEK. Abschlussbericht zur Weiterentwicklung des DRG-Systems für 2009 [online]. Available from URL: . de/upload/Abschlussbericht-G-DRG-Sys tem-2009-4249.pdf [Accessed 2011 Jan 20]
29. German Federal Insurance Office (BVA) expertise 2001 [online]. Available from Anhang-A-Korrektur.html [Accessed 2011 Jan 20]
30. Brüggenjürgen B, Rupprecht HJ, Willich SN, et al. Cost of atherothrombotic diseases-myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease-in Germany. J Public Health 2005; 13: 216-24 (Pubitemid 41040220)
31. Neumann PJ, Gelbrich G, Mostardt S, et al. Gesundheitsö-konomische Evaluation der INH (interdisziplinäres Netzwerk Herzinsuffizienz) Studie. Poster Presentation at 75th Annual Meeting of the German Cardiac Society, Mannheim, 2009
32. Winter Y, Wolfram C, Schöffski O, et al. Langzeitkrankheitskosten 4 Jahre nach Schlaganfall oder TIA in Deutschland. Nervenarzt 2008; 79: 918-26
33. Scherbaum WA, Goodall G, Erny-Albrecht KM, et al. Costeffectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective. Cost Eff Resour Alloc 2009; 7: 9
34. Valentine WJ, Goodall G, Aagren M, et al. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modeling study of long-term clinical and cost outcomes. Adv Ther 2008; 25: 567-84
35. Palmer AJ, Annemans L, Roze S, et al. GesundheitsökonomischeAspekte der Anwendung von Irbesartan in Deutschland. [Health economic consequences of irbesartan treatment of type 2 diabetes patients with hypertension and nephropathy in Germany]. Dtsch Med Wochenschr 2004; 129: 13-8 (Pubitemid 38091033)
36. DCCT Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am J Med 1991; 90: 450-9
37. Kassenärztliche Bundesvereinigung (KBV). Beschluss des Erweiterten Bewertungsausschusses gemäX y 87 Abs. 4 SGB V zur Weiterentwicklung der vertragsärztlichen Vergütung im Jahr 2010 in seiner 15. Sitzung am 2. September 2009 [online]. Available from URL: ebm2010/EBMGesamt.htm [Accessed 2011 Jan 20]
38. Institut für das Entgeltsystem im Krankenhaus gGmbH (Institute for the Remuneration System in Hospitals (InEK)) (2009): G-DRG V2008/2010 Report-Browser, fully in-patient ward ("Hauptabteilung") [online]. Available from URL: -site-de/layout/set/standard/G-DRG-System-2010/Abschluss bericht-zur-Weiterentwicklung-des-G-DRG-Systems-und- Report-Browser/Report- Browser-2008-2010 [Accessed 2011 Jan 20]
39. InEK (2009): Abschlussbericht Weiterentwicklung des GDRG-Systems für das Jahr 2010 [online]. Available from URL: 18-Abschlussbericht-2010-10824.pdf [Accessed 2011 Jan 20]
40. InEK (2009): G-DRG-Fallpauschalen-Katalog 2010 nebst Anlagen [online]. Available from URL: downloads/19-0Fallpauschalenkatalog-2010-090930.pdf [Accessed 2011 Jan 20]
41. Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ 2009; 12: 281-90
42. United Kingdom Department of Health. Health Survey for England 2003 [online]. Available from URL: . gov.uk/en/PublicationsAndStatistics/ PublishedSurvey/Health SurveyForEngland/HealthSurveyResults/DH-4098913 [Accessed 2011 Jan 20]
43. Clarke P, Gray A, Holman R, et al. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 2002; 22: 340-9 (Pubitemid 34791321)
44. Caro JJ, Stillman IP, Danel A, et al. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model. J Med Econ 2007; 10: 239-54 (Pubitemid 47478747)
45. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-34 (Pubitemid 44297431)
46. Guidelines of German Institute for Quality and Efficiency in Health Care (IQWiG) [online]. Available from URL: http://www.iqwig.de [Accessed 2011 Jan 20]
47. Neeser K, Lübben G, Siebert U. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a German statutory healthcare perspective. Pharmacoeconomics 2004; 22: 321-41 (Pubitemid 38553703)
48. Shearer AT, Bagust A, Liebl A, et al. Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany. Pharmacoeconomics 2006; 24 Suppl. 1: 35-48
49. Mittendorf T, Smith-Palmer J, Timlin L, et al. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: costeffectiveness analysis in the German setting. Diabetes, Obesity and Metabolism 2009: 1068-79
50. Eberhart MS, Ogden C, Engelgau M, et al. Prevalence of overweight and obesity among adults with diagnosed diabetes United States, 1988-1994 and 1999-2002. Morb Mortal Wkly Rep (MMWR) 2004; 53 (45): 1066-8
51. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-21
52. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010; 122 (3): 71-80
53. Billiones R. Saxagliptin in type 2 diabetes. Drugs Today (Barc) 2010; 46: 101-8
54. Pollack M, Chastek B, Williams SA. Impact of treatment complexity on adherence and glycemic control: an analysis of oral anti-diabetic agents. Presented at International Society for Pharmacoeconomics and Outcomes Research 14th Annual International Meeting 2009 May 16-20; Orlando (FL): PDB36
55. Kulasa K, Edelman S. Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus. Core Evid 2010 Oct 21; 5: 23-37
56. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-22
57. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-55